Cognition Therapeutics Inc (CGTX) stock
CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.60−0.03 (-4.75%)
Close on Nov 18, 2026Market cap $57.06MP/E –Yield –
Cognition Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cognition Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$17.68M. For fiscal 2025 it was -$24.59M. The highest annual figure on record is -$3.43M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.59M | – |
| FY2024 | Dec 31, 2024 | -$28.47M | – |
| FY2023 | Dec 31, 2023 | -$16.02M | – |
| FY2022 | Dec 31, 2022 | -$18.53M | – |
| FY2021 | Dec 31, 2021 | -$3.63M | – |
| FY2020 | Dec 31, 2020 | -$3.43M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.44M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.65M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.88M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.24M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.46M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.18M | -10183.2% |
| Q3 FY2022 | Sep 30, 2022 | -$4.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.99M | – |
| Q4 FY2021 | Dec 31, 2021 | $101.00K | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$910.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$772.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$480.00K | – |
See a number that looks wrong?